Cargando…
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study
It is generally recommended that patients with splanchnic vein thrombosis (SVT) should receive a minimum of 3 months of anticoagulant treatment. However, little information is available on the long-term risk of recurrent thrombotic events. The aim of this study was to evaluate the risk of venous and...
Autores principales: | Riva, Nicoletta, Ageno, Walter, Poli, Daniela, Testa, Sophie, Rupoli, Serena, Santoro, Rita, Lerede, Teresa, Piana, Antonietta, Carpenedo, Monica, Nicolini, Alberto, Ferrini, Piera Maria, Martini, Giuliana, Mangione, Catello, Contino, Laura, Bonfanti, Carlo, Gresele, Paolo, Tosetto, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609867/ https://www.ncbi.nlm.nih.gov/pubmed/26508913 http://dx.doi.org/10.1155/2015/620217 |
Ejemplares similares
-
Splanchnic Vein Thrombosis: Current Perspectives
por: Valeriani, Emanuele, et al.
Publicado: (2019) -
Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions
por: Riva, Nicoletta, et al.
Publicado: (2020) -
Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study
por: Ageno, Walter, et al.
Publicado: (2022) -
Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette‐based survey
por: Riva, Nicoletta, et al.
Publicado: (2020) -
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study
por: Palareti, Gualtiero, et al.
Publicado: (2019)